

ALL. B

Decreto Rettore Università di Roma “La Sapienza” n. 1274/2023 del 23/05/2023

**“Procedura selettiva per la copertura di n. 1 posto di Prof. di ruolo di II fascia, Settore concorsuale 06/A2 – Settore scientifico disciplinare MED/04, presso il Dipartimento di Medicina Molecolare - Facoltà di Farmacia e Medicina-codice concorso 2023PAE017”**

## **VERONICA VESCHI**

### **Curriculum Vitae**

Place, Rome

Date, 19<sup>th</sup> June 2023

#### **Part I – General Information**

Full Name	Veronica Veschi
Spoken Languages	Italian; English

#### **Part II – Education**

Type	Year	Institution	Notes (Degree, Experience)
PhD	2014	University “La Sapienza”, Rome, Italy	PhD in Molecular Medicine
Graduate Partnership Program	2013/2014	National Institutes of Health (NIH), Bethesda, MD, USA	Graduate Partnership Program graduation award recipient
Specialty	2011	University “La Sapienza”, Rome, Italy	Specialty in Oncology 70/70 “ <i>summa cum laude</i> ”
Licensure	2007	University “La Sapienza”, Rome, Italy	Licensure in Medicine, Qualification to the profession of Medical Doctor, Order of Medical Doctors and Surgeons, Province of Rome n. 55791
University graduation	2006	Faculty of Medicine and Surgery, Degree course in Medicine and Surgery (M.D.), University “La Sapienza”, Rome, Italy	Master Degree Graduation 110/110 “ <i>summa cum laude</i> ”

### Part III – Appointments

#### IIIA – Academic Appointments

Start	End	Institution	Position
April 2023	May 2023	Catholic University of Sacred Heart, Rome, Italy	Research collaborator funded by “Company Americana HiberCell”
March 2020	March 2023	University of Palermo, Palermo, Italy	Researcher RTDA-Ricercatore a tempo determinato di Tipo A (MED/46) co-funded by European Social Fund-PON AIM
January 2019	February 2020	University of Palermo, Palermo, Italy	Research collaborator funded by Adriano Buzzati-Traverso Foundation (FABT)
December 2016	December 2018	University of Palermo, Palermo, Italy	Post-doctoral Fellow awarded by the Adriano Buzzati-Traverso Foundation (FABT) and funded by “Associazione Italiana per la ricerca contro il cancro (AIRC)”
November 2011	December 2014	University “La Sapienza”, Rome, Italy	PhD student, Dottorato in Medicina Molecolare, XXVII ciclo (Titolare di borsa triennale)
August 2011	October 2011	University “La Sapienza”, Rome, Italy	Assegnista di Ricerca funded by University “La Sapienza”
August 2007	July 2011	University “La Sapienza”, Rome, Italy	Specializzanda in Oncologia (Titolare di contratto)

#### IIIB – Other Appointments

Start	End	Institution	Position
June 2023	May 2024	IFO-Istituto Nazionale Tumori Regina Elena e Istituto Dermatologico San Gallicano, Rome, Italy	Research collaborator funded by “Cod. IFO Ricerca Corrente 2023”
November 2016	November 2018	National Institutes of Health (NIH), Bethesda, MD, USA	Special Volunteer NIH
February 2013	November 2016	National Institutes of Health (NIH), Bethesda, MD, USA	Visiting Fellow (Pre and Post-doctoral) funded by NIH

#### IIIC – Periodi di allontanamento non volontario dall’attivit  di ricerca, come richiesto da Bando

Start	End	Institution	Due to
August 2019	January 2020	University of Palermo, Palermo, Italy	Maternity leave

## IIID – Abilitazioni ASN

Start	End	Institution	Position
June 2022	June 2033	National scientific qualification (Bando 2021/2023-DD553/2021)	Abilitazione Scientifica Nazionale II Fascia SC 06/A2 – MED/04
June 2022	June 2033	National scientific qualification (Bando 2021/2023-DD553/2021)	Abilitazione Scientifica Nazionale II Fascia SC 06/N1 – MED/46

## Part IV – Teaching experience

Year	Institution	Lecture/Course
2020/2022	University of Palermo, Palermo, Italy	Teacher of “Basic professional laboratory” – Degree Course of Techniques of Biomedical Laboratory – code 17668 (3 credits)
2020/2022	University of Palermo, Palermo, Italy	Teacher of “Epigenetic and cancer”– ADO seminar, Degree Course of Medicine and Surgery and Degree Course of Techniques of Biomedical Laboratory – code 21598 (3 credits)
2019/2022	University of Palermo, Palermo, Italy	Tutor and Thesis co-supervisor for PhD students in “Molecular and Clinical Medicine” and for students in Degree Courses of “Techniques of Biomedical laboratory” and “Biotechnologies”
2019/2022	University of Palermo, Palermo, Italy	Tutor for student internship in “Basic professional laboratory”, Degree Course of Techniques of Biomedical Laboratory (3 credits)
2018/2020	University of Palermo, Palermo, Italy	Culture della materia per l’insegnamento di Patologia Generale (MED/04) nel corso di Laurea in Medicina e Chirurgia
2018/2020	University of Palermo, Palermo, Italy	Culture della materia per l’insegnamento di Scienze Tecniche di Medicina di Laboratorio (MED/46) nel corso di Laurea in Tecniche di Laboratorio Biomedico

## Part V – Other Professional Activities

Year	Title
2018-present	Ad hoc Reviewer for International Journals ( <i>Communications Biology; Oncogenesis; Molecular Cancer; Genomics; International Journal of Molecular Sciences; Biomolecules; Cancers; Frontiers in Immunology; Cancer Reports and Reviews; Journal of Stem Cells &amp; Regenerative Medicine</i> )
2023-present	Topic Editor for <i>Biomedicine</i> , Special Issue “Novel Insights in Cancer Stem Cells”
2021-present	Review Editor for <i>Frontiers in Molecular Medicine</i> , Section “Cell Therapy”, Research Topic “Epigenetics and stem cell therapy in cancer and diseases”
2021-2022	External Reviewer for Doctoral Thesis of PhD students in Molecular Medicine, University of Rome "La Sapienza", cycle: XXXIV
2020-present	Topic Editor for <i>Biomolecules</i> , Special Issue “Cancer Epigenetics Drug Discovery and Development”
2018	Member of the Judging Commission of the awards for the best posters and poster presentation, at the international scientific congress “60th annual meeting of the Italian Cancer Society (SIC)”, Milan, Italy

## Part VI - Society memberships, Awards and Honors

### A – Society memberships

Year	Title
2019-present	Membership of Società Italiana di Ricerca Traslazionale e delle Professioni Sanitarie (SIRTEPS)
2018-present	Membership of European Association for Cancer Research (EACR)
2017-present	Membership of Associazione Italiana di Biologia Cellulare e del Differenziamento (ABCD)
2017-present	Membership of Società Italiana di Cancerologia (SIC)
2015- present	Membership of American Association for Cancer Research (AACR)
2014- present	Membership of Advances in Neuroblastoma Research Association (ANRA)

### B – Awards

Year	Title
2023	Prize “Alberto Gulino” Best Oral Presentation titled “ <i>Ricapitulating thyroid cancer histotypes through engineering embryonic stem cell</i> ” at the 3 MEETING S.I.R.T.E.P.S., Session III: Integrative Omics approaches: Clinical Implication, Favignana, Italy
2020	“Best Paper Award 2020” for the study titled “ <i>Targeting chemoresistant colorectal cancer via systemic administration of a BMP7 variant</i> ” Veschi et al. <i>Oncogene</i> 2020, assigned by the Department of Oncological and Stomatological Surgical Disciplines (DICHIRONS), University of Palermo, Italy
2019	“FABT Award” for the Research Activity on the Isolation and Characterization of Cancer Stem Cells in Thyroid and Colorectal cancers assigned by the Adriano Buzzati-Traverso Foundation (FABT), Rome, Italy
2018	“Best Poster Award, Translational, young investigator” for a poster titled “ <i>Tailoring epigenetic precision therapy in neuroblastoma: SGSS05-NS3 as a potent and selective pharmacological inhibitor of SETD8 that rescues p53 functions</i> ” assigned by the American Advances in Neuroblastoma Research Association (ANR) at the Congress “Building Bridges: ANR Advances in Neuroblastoma research” San Francisco, USA.
2017	“Travel grant fellowship ABCD Pre-congress 2017 award” for a poster titled “ <i>Dissecting the epigenetic landscape in CD44v6<sup>+/-</sup> colon cancer cell subsets as a novel strategy of tailored therapy</i> ” assigned by the Association of Cell Biology and Differentiation (ABCD), at the “Biennial Congress of the Italy Association of Cell Biology and Differentiation (ABCD)”, Bologna, Italy
2017	“AACR-Aflac, Inc. Scholar-in-Training Award” for a poster titled “ <i>Epigenetic siRNA and chemical screens identify SETD8 inhibition as a therapeutic strategy to reactivate p53 in high-risk Neuroblastoma</i> ”, conferred by the American Association for Cancer Research (AACR), at the conference “AACR Annual meeting 2017” Washington DC, USA
2017	“17th CCR-FYI Colloquium Travel Award for Outstanding Oral Presentation”, titled “ <i>SETD8 and p53: future prognostic and therapeutic applications in cancer</i> ”, assigned by the Center for Cancer Training, National Institutes of Health, at the conference “17th annual CCR-FYI Colloquium, The Era of Gene Editing-Overcoming Today's Challenges for Tomorrow's Cure”, Shady Grove Rockville, MD, USA.
2016	“Crystal Mackall Excellence in Research Award” for outstanding research activity on Neuroblastoma Epigenetic Regulators, conferred by the Pediatric Oncology Branch, Center for Cancer Research, National Institutes of Health, Bethesda, MD, USA

2015	“Outstanding graduate research international award” for the research activity during the pre-doctoral fellowship at National Institutes of Health and "GPP (Graduate Partnership Program) graduation award” recipient for PhD thesis dissertation, Bethesda, MD, USA
------	--

#### C – Awarded Fellowships

Year	Title
2023-2024	Fellowship awarded by Istituto Dermatologico San Gallicano and financed by Ricerca Corrente 2023 within the project titled " <i>Biomarkers in tumors</i> "- <i>Study of epigenetic mechanisms of p53 regulation in melanoma cancer stem cells</i>
2018	Post-doctoral Fellowship awarded by the Adriano Buzzati-Traverso Foundation (FABT) and financed by the Italian Association for Cancer Research (AIRC) within the project titled " <i>Molecular mechanisms underlying thyroid cancer metastasis: emergence from tumor dormancy</i> "
2016-2018	Post-doctoral Fellowship awarded by the Adriano Buzzati-Traverso Foundation (FABT) and financed by the Italian Association for Cancer Research (AIRC) within the project titled " <i>Development of effective cancer therapies based on functional proteomics and cancer stem cell targeting</i> "

#### D – Honors

Year	Title
2023	Research Highlights in <i>Nature Reviews Endocrinology 2023</i> “Engineering stem cells to recapitulate thyroid cancer” for the study Veschi et al. <i>Nature Communications 2023</i>
2017-2018	Milestones-Highlights 2017-2018 “ <i>Epigenetic Screen Identifies SETD8 as a target in High-risk Neuroblastoma</i> ” as one of the top 10 scientific advances in Center for Cancer Research (CCR) for FY2017. The studies carried out at the National Institutes of Health (NIH), published in <i>Veschi et al. Cancer Cell 2017</i> were selected among the top 10 scientific impact results of 2017 in the Center for Cancer Research, NIH.
2017	Oncoscience Editorial “ <i>High-SETD8 inactivates p53 in neuroblastoma</i> ” for the study <i>Veschi et al. Cancer Cell 2017</i>
2017	Cancer Discovery Editorial “ <i>SETD8 Inhibition Activates p53 in High-Risk Neuroblastoma</i> ” for the study <i>Veschi et al. Cancer Cell 2017</i>

#### Part VII - Funding Information [grants as PI-principal investigator or I-investigator]

Year	Title	Program	Grant value
2023-2024	<b>PI</b> in the project: “Study of the epigenetic mechanisms of p53 regulation in macrophages associated with colorectal cancer”	“ProgRic 2022 Misura I.1.a Progetti presentati da singoli ricercatori”, awarded and funded by University of Palermo	2.000,00 €
2023	<b>PI</b> in the project: “CD44v6 as a therapeutic target for the treatment of Glioblastoma”	“EUROSTART-2023” awarded and funded by University of Palermo	16.100,00 €

2022	<b>I</b> in the project: “The role of the EPO-EPOR complex in glioma: identification of novel biomarkers to develop new therapeutic strategies”	“EUROSTART-2022” awarded and funded by University of Palermo	10.000,00 €
2022-2024	<b>I</b> in the project: “Dissecting the biology of early-onset colorectal cancer”	PNRR-Ministero della Salute-PNRR-MAD-2022-12376835	1.134.500,00 €
2020-2023	<b>PI</b> in the project: "The epigenetic inactivation of p53 as a therapeutic target in colorectal cancer stem cells”	PON AIM Line 1, PON Research and Innovation 2014-2020 cofunded by the European Social Fund (AIM1892002-2)	14.656,14 €
2020-2023	<b>I</b> in the project: “BMP7v role and dormancy in colorectal cancer”	American Company “HiberCell”	594.000,00 \$
2020-2023	<b>I</b> in the project: “Isolation and characterization of metastatic cancer stem cells as preclinical model for advanced colorectal cancer treatment”	Ricerca Finalizzata 2018 (RF2018-12367044)	590.000,00 €
2019-2022	<b>I</b> in the project: “Adiponcosis: paving the road between obesity and cancer”	PRIN 2017 (2017WNKSLR)	1.199.898,50 €
2019-2023	<b>I</b> in the project: “Genetic Mutation Model: unveiling the pathogenetic mechanisms of thyroid carcinoma”	AIRC IG 2018 #21445	1.482.668,00 €
2018-2021	<b>I</b> in the project: “Green processes for the extraction of active ingredients and the purification of waste and not waste matrices”	PON (acronym-PROGEMA) #ARS01_00432	8.042.640,00 €
2016-2018	<b>I</b> in the project: “Molecular mechanisms underlying thyroid cancer metastasis: emergence from tumor dormancy”	AIRC IG 2015 # 16746	697.854,00 €
2016-2018	<b>I</b> in the project: “Development of effective cancer therapies based on functional proteomics and cancer stem cell targeting”	AIRC 5x1000 Molecular Clinical Oncology Extension Program #9979	440.224,00 €
2013-2014	<b>I</b> in the project: “Epigenome focused RNAi screen to identify druggable targets in neuroblastoma”	St. Baldrick’s Foundation Research Grant 2012-2014	100.000,00 \$
2011-2014	<b>I</b> in the project: “Crosstalk between the DNA Damage Response pathway and MYCN in neuronal development and carcinogenesis”	AIRC IG 2011 # 12116	240.000,00 €
2011-2012	<b>I</b> in the project: “Understanding the molecular functions of Myc proteins at the border between proliferation and apoptosis: implications for new therapies”	FINANZIAMENTO RICERCA ATENEO 2011 # C26A11C4LT “La Sapienza” University	15.000,00 €

## Part VIII – Research Activities

Keywords	Brief Description
Epigenetics	Identification of the epigenetic regulators with a key role in Neuroblastoma and colorectal cancer tumorigenesis, with particular focus on SETD8 and its histone/non-histone targets; screening of chemical libraries including small molecules and compounds inhibiting epigenetic regulators.
Cancer stem cells	Isolation and Characterization of Cancer stem cells (CSC) subpopulation in several tumors, including Colorectal cancer, Thyroid carcinomas, Breast cancer and Glioblastoma, identifying the main properties of CSCs endowed with metastatic potential.
p53	Study of the post-translational mechanisms of p53 regulation and its functional inactivation in cancer stem cells and tumor-associated macrophages during tumor initiation and progression.
Neuroblastoma	Mechanisms through which MYCN sensitizes Neuroblastoma cells to apoptosis; identification of the epigenetic enzymes and chromatin remodelers that crucially regulates Neuroblastoma cells proliferation and differentiation.
Colorectal cancer	Development of effective therapeutic strategies targeting cancer stem cells and their microenvironment; study of adipose tissue contribution to colorectal tumorigenesis; development of natural compounds able to differentiate and target colorectal CSCs.
Thyroid cancer	Development of 3D-models recapitulating follicular cell-derived thyroid cancer histotypes by using human embryonic stem cells and CRISPR-Cas9 technologies; identification of molecular mechanisms underlying thyroid cancer tumorigenesis and metastasis.

Main results attained:

1. Identification of the epigenetic regulators with a key role in Neuroblastoma (NB) tumorigenesis, with particular focus on SETD8: *i*) identification of 16 potentially druggable epigenetic regulators critical for both the uncontrolled proliferation and the differentiation block in high-risk NBs; *ii*) SETD8, the H4<sup>K20me1</sup> methyl transferase which also monomethylates p53 on lysine 382 (p53<sup>K382me1</sup>) inhibiting p53 pro-apoptotic and growth arrest functions, was identified as a crucial regulator of NB proliferation and differentiation; *iii*) SETD8 was validated as a druggable therapeutic target in NB by using a small-molecule inhibitor of SETD8, UNC0379; *iv*) SETD8 inhibition activates the p53 canonical pathway by decreasing p53<sup>K382me1</sup> levels, thus rescuing the pro-apoptotic and growth-arrest p53 functions; *v*) identification of a previously unknown mechanism of p53 inactivation in NB, particularly in the majority of NBs (75%) MYCN WT.
2. Mechanisms through which MYCN sensitizes Neuroblastoma (NB) cells to apoptosis: *i*) study of the role of Galectin-3 as a regulator of apoptosis and differentiation in NB, defining it as a relevant prognostic marker; *ii*) MYCN activates an effective response to DNA damage that leads to cell death by the induction of the p53 (S46) kinase HIPK2; *iii*) identification of essential pathogenic mechanisms underlying the molecular axis HIPK2-p53-Galectin3, which can be activated by the non-genotoxic p53-reactivating compound Nutlin-3, suggesting that this pathway can be targeted by a tailored p53 reactivating therapy in patients with high-risk NB.

3. Development of effective therapeutic strategies targeting cancer stem cells (CSCs) and their microenvironment in colorectal cancer (CRC): *i*) identification of a BMP7 variant (BMP7v) characterized by improved stability and solubility, which sensitizes the colorectal CSCs (CR-CSCs) to chemotherapy and induces their differentiation in *in vitro* and *in vivo* CRC models; *ii*) study of IL-6 and HGF produced by stromal cells of tumor visceral adipose tissue able to promote the expansion of metastatic CR-CSCs CD44v6<sup>+</sup>, which in turn secrete neurotrophins that recruit adipose stem cells within the tumor mass, supporting that the targeting of fat-derived factors may prevent metastatic disease in obese CRC patients; *iii*) identification of the triple targeting of HER2, MEK and PI3K as an effective strategy able to induce CR-CSCs cell death and the regression of CRC resistant to anti-EGFR therapy, including CRC mutated in KRAS and PIK3CA; *iv*) identification of the combinatorial treatment based on the neosynthetic alkaloid NORA234 in association with the CHK1 inhibitor, rabusertib, which promotes cell death of both CD44v6<sup>+</sup> and CD44v6<sup>-</sup> CR-CSCs compartments; *v*) identification of a therapeutic strategy based on natural flavonoids, polymethoxyflavones and prenylflavonoids, which improves the efficacy of chemotherapy, reduces the expression of CD44v6, a marker of CR-CSCs endowed with metastatic potential, and inhibits Wnt signaling pathway.
  
4. Development of novel models of the most common thyroid cancer (TC) histotypes: *i*) follicular cell-derived thyroid cancer histotypes were recapitulated based on the induction of specific genomic alteration delivered by CRISPR-Cas9 in human embryonic stem cells (hESC)-derived thyroid progenitor cells (TPCs) at day 22; *ii*) TPCs harboring BRAF<sup>V600E</sup> or NRAS<sup>Q61R</sup> mutations generate papillary or follicular TC, respectively, whereas addition of TP53<sup>R248Q</sup> generate undifferentiated TCs; *iii*) identification of the ternary complex TIMP1-MMP9-CD44, which sustains the tumor initiation capability of engineered day 22 TPCs; *iv*) identification of KISS1R as a prognostic factor and a potential therapeutic target in advanced and metastatic TCs; *v*) design of a novel combinatorial treatment targeting TIMP1 and KISS1R, which restores the functional iodine uptake by increasing NIS expression and may represent a therapeutic adjuvant option for undifferentiated TCs.

## Part IX – Invited Oral Presentations at National and International Meetings

Year	Title
2023	Invited Speaker at the scientific conference “Third Meeting S.I.R.T.E.P.S (Societa’ Italiana Ricerca Traslazionale e Professioni Sanitarie) - Precision medicine in the era of the integrated omics” in Favignana, Italy. Oral presentation titled “ <i>Recapitulating thyroid cancer histotypes through engineering embryonic stem cell</i> ”
2022	Invited Speaker at the international scientific conference “12 <sup>th</sup> European workshop on Cell Death (EWCD)” in Fiuggi, Italy. Oral presentation titled “ <i>SETD8-mediated p53 inactivation as an early prerequisite of inflammation-induced colorectal cancer</i> ”
2021	Invited Speaker of a lecture at the international scientific Webinar “Laboratory of Cell Biology, Branch Program”, National Institutes of Health (NIH), Bethesda, MD, USA. Lecture titled “ <i>Inflammation-induced epigenetic reprogramming and colon cancer evolution: p53 regulation in cancer stem cells</i> ”
2020	Invited Speaker at the “Best paper award DICHIRONS 2020-Webinar”, University of Palermo, Italy. Oral presentation titled “ <i>Targeting chemoresistant colorectal cancer via systemic administration of a BMP7 variant</i> ”



2019	Invited Speaker at the “Joint meeting University of Palermo - Catholic University of the Sacred Heart, Rome - HiberCell: Future perspectives on the BMP7v molecule”, University of Palermo, Italy. Oral presentation titled “ <i>BMP7v collaborative research proposal</i> ”
2018	Invited Speaker at the international scientific conference “Building Bridges: ANR Advances in Neuroblastoma research” San Francisco, California, USA. Oral presentation titled “ <i>Tailoring epigenetic precision therapy in neuroblastoma: SGSS05-NS3 as a potent and selective pharmacological inhibitor of SETD8 that rescues p53 functions</i> ”
2017	Invited Speaker at the international scientific conference “17 <sup>th</sup> annual CCR-FYI Colloquium, The Era of Gene Editing-Overcoming Today’s Challenges for Tomorrow’s Cure” National Cancer Institute (NCI), Shady Grove Rockville, MD, USA. Oral presentation titled “ <i>SETD8 and p53: future prognostic and therapeutic applications in cancer</i> ”
2016	Invited Speaker of a lecture at the international scientific seminar “Pediatric Oncology Branch Research Seminar” accredited as an ECM activity, presented by the Johns Hopkins University School of Medicine and the National Institutes of Health, Bethesda, MD, USA. Lecture titled “ <i>Epigenetic siRNA and chemical screens identify novel therapeutic targets in Neuroblastoma</i> ”
2016	Invited Speaker of a lecture at the international scientific seminar “Laboratory of Cell Biology, Branch Program”, National Institutes of Health (NIH), Bethesda, MD, USA. Lecture titled “ <i>Epigenetic siRNA and chemical screens identify novel therapeutic targets in Neuroblastoma</i> ”
2016	Invited Speaker at the international scientific conference “4 <sup>th</sup> Developmental Biology Workshop”, National Institutes of Health (NIH), Bethesda, MD, USA. Oral presentation titled “ <i>Epigenetic regulators critical in reprogramming Neuroblastoma tumor cells to differentiate</i> ”
2016	Invited Speaker at the international scientific conference “16 <sup>th</sup> annual CCR-FYI Colloquium, Pipettes to Syringes: Collaborating for a Cure” National Cancer Institute (NCI), Shady Grove Rockville, MD, USA. Oral presentation titled “ <i>Epigenetic siRNA and chemical screens identify SETD8 inhibition as a novel therapeutic strategy and a new mechanism of p53 reactivation in high-risk Neuroblastoma</i> ”
2015	Invited Speaker at the international scientific seminar “Pediatric Oncology Branch, POB Round Up” National Institutes of Health (NIH), Bethesda, MD, USA. Oral presentation titled “ <i>Epigenetic focused siRNA and chemical screens identify novel druggable targets for high-risk Neuroblastoma</i> ”
2014	Invited Speaker at the international scientific conference “14 <sup>th</sup> annual CCR-FYI Colloquium, Making research count, from the bench to the bedside” Advanced Technology Research facility, Frederick, MD, USA. Oral presentation titled “ <i>An Epigenetic focused siRNA screen identifies novel druggable targets that inhibit growth and induce differentiation in Neuroblastoma</i> ”

## Part X – Summary of Scientific Achievements

Product type	Number	Data Base	Start	End
Papers [international]	30	Pubmed, ISI Web of Science, Scopus	2008	2023
Papers [international]	3	Crossref	2022	2023
Books [scientific]	1 (Chapter)	Editor Springer International Publishing AG, Cham	2018	2023
Books [teaching]	1	Editor Medical Books	2018	2023

### Total Publications indexed on Pubmed (30 publications)

Total Impact factor	264,459 (relative to publication year)
Average Impact factor for publication	8,81
Total Citations	728 (Scopus)
Average Citations per Product	24,26
Hirsch (H) index	17 (Scopus)
Normalized H index*	1,13

\*H index divided by the academic seniority.

### Publications of the last 10 years indexed on Pubmed (26 publications)

Total Impact factor	242,064
Average Impact factor for publication	9,31
Total Citations	637 (Scopus)
Hirsch (H) index	16

### Active Impact Factor (IF)

Number of papers as First, Last, or Corresponding Author (all journals)	13
Number of papers as First, Last, or Corresponding Author (journals with IF)	10
Total IF as first, co-first, co-corresponding and last author	100,202
Average IF as first, co-first, co-corresponding and last author	10,02

### Active Impact Factor (IF) in International Journals with IF>5

Number of papers as First, Last, or Corresponding Author (all journals with IF>5)	6
Total IF as first, co-first, co-corresponding and last author	85,607
Average IF as first, co-first, co-corresponding and last author	14,27

## Part XI– Selected Publications

List of the publications selected for the evaluation. For each publication report title, authors, reference data, journal IF\* (if applicable), citations\*\*, press/media release (if any).

Notes:

\*Journal Impact Factors of the year of publication are indicated.

\*\*Scopus was used to calculate citations.

### 1. Recapitulating thyroid cancer histotypes through engineering embryonic stem cells.

**Veschi V.**, Turdo A., Modica C., Verona F., Di Franco S., Gaggianesi M., Tirro' E., Di Bella S., Lo Iacono M., Pantina V.D., Porcelli G., Mangiapane L. R., Bianca P., Rizzo A., Sciacca E., Pillitteri I., Vella V., Belfiore A., Bongiorno M.R., Pistone G., Memeo L., Colarossi L., Giuffrida D., Colarossi C., Vigneri P., Todaro M., and Stassi G.

*Nat Commun.* 2023 Mar 11;14(1):1351. doi: 10.1038/s41467-023-36922-1. PMID: 36906579.

**IF: 17.694 Citations: 1**

PRESS/MEDIA RELEASE:

<https://siciliamedica.com/articoli/tumore-avanzato-alla-tiroide-team-di-unipa-scopre-potenziabile-terapia/?fbclid=IwAR1oluiYuiT8oI1RCFa-xN95yL5gyb4-iTQFKnGHPMzqPH4wNyesVNYe7es>

<https://www.rainews.it/tgr/sicilia/notiziari/index.html?/tgr/video/2020/05/ContentItem-d2c4000a-f6e4-4317-8448-cf9cef0b8523.html> minutes 7:22-12:50

[https://www.unipa.it/Identificata-potenziabile-terapia-per-le-forme-avanzate-di-tumore-alla-tiroide--La-scoperta-del-team-UniPa-coordinato-dal-prof.-Giorgio-Stassi-pubblicata-su-Nature-Communications/?fbclid=IwAR1wTpl3Qy\\_Gf7bDr3zwt99o49HriYIUo58EfNwbq6gCYK7SHX\\_TW8FBYXY](https://www.unipa.it/Identificata-potenziabile-terapia-per-le-forme-avanzate-di-tumore-alla-tiroide--La-scoperta-del-team-UniPa-coordinato-dal-prof.-Giorgio-Stassi-pubblicata-su-Nature-Communications/?fbclid=IwAR1wTpl3Qy_Gf7bDr3zwt99o49HriYIUo58EfNwbq6gCYK7SHX_TW8FBYXY)

### 2. Effective targeting of breast cancer stem cells by combined inhibition of Sam68 and Rad51.

Turdo A, Gaggianesi M, Di Franco S, **Veschi V**, D'Accardo C, Porcelli G, Lo Iacono M, Pillitteri I, Verona F, Militello G, Zippo A, Poli V, Fagnocchi L, Beyes S, Stella S, Lattanzio R, Faldetta N, Lentini VL, Porcasi R, Pistone G, Bongiorno MR, Stassi G, De Maria R, Todaro M.

*Oncogene.* 2022 Apr;41(15):2196-2209. doi: 10.1038/s41388-022-02239-4. Epub 2022 Feb 25. PMID: 35217791.

**IF: 8.756 Citations: 4**

PRESS/MEDIA RELEASE:

[https://www.unipa.it/Cancro-al-seno--Studio-sostenuto-da-AIRC-e-coordinato-da-UniPa-identifica-un-mecanismo-che-determina-la-resistenza-alle-terapie-/?fbclid=IwAR3Wmytm3\\_lDI9MHUZa0hFYz5bNaWM5wNKueQcGthJ6pR3ysRsJ\\_iKPF\\_-0](https://www.unipa.it/Cancro-al-seno--Studio-sostenuto-da-AIRC-e-coordinato-da-UniPa-identifica-un-mecanismo-che-determina-la-resistenza-alle-terapie-/?fbclid=IwAR3Wmytm3_lDI9MHUZa0hFYz5bNaWM5wNKueQcGthJ6pR3ysRsJ_iKPF_-0)

[https://www.linkedin.com/posts/unipa-dichirons\\_effective-targeting-of-breast-cancer-stem-activity-6904443849490731009-mCIF?fbclid=IwAR1eV4LTftpYSbt-bnhxnQJ9LRvkXCeanNttUrWoSz63Wdxhyb50OoSfWf0Y](https://www.linkedin.com/posts/unipa-dichirons_effective-targeting-of-breast-cancer-stem-activity-6904443849490731009-mCIF?fbclid=IwAR1eV4LTftpYSbt-bnhxnQJ9LRvkXCeanNttUrWoSz63Wdxhyb50OoSfWf0Y)

<https://lnkd.in/dkc86SfP>

**3. PI3K-driven HER2 expression is a potential therapeutic target in colorectal cancer stem cells.**

Mangiapane LR, Nicotra A, Turdo A, Gaggianesi M, Bianca P, Di Franco S, Sardina DS, **Veschi V**, Signore M, Beyes S, Fagnocchi L, Fiori ME, Bongiorno MR, Lo Iacono M, Pillitteri I, Ganduscio G, Gulotta G, Medema JP, Zippo A, Todaro M, De Maria R, Stassi G.

*Gut*. 2022 Jan;71(1):119-128. doi: 10.1136/gutjnl-2020-323553. Epub 2021 Jan 12. PMID: 33436496.

**IF: 31.795 Citations: 35**

PRESS/MEDIA RELEASE:

[https://www.fattieavvenimenti.it/palermo-il-tumore-al-colon-si-puo-sconfiggere-scoperto-punto-debole-al-policlinico-giacone/?fbclid=IwAR1hGrhAjmzR3fthJD-ykLeQAVo-No2E9s6vXtnX\\_veKp4o1piNPRXbsgkc](https://www.fattieavvenimenti.it/palermo-il-tumore-al-colon-si-puo-sconfiggere-scoperto-punto-debole-al-policlinico-giacone/?fbclid=IwAR1hGrhAjmzR3fthJD-ykLeQAVo-No2E9s6vXtnX_veKp4o1piNPRXbsgkc)

[https://m.youtube.com/watch?v=msxnH-LeIM4&feature=share&fbclid=IwAR2B9Sf\\_kThKE8xlz1Ex8tRsufoiq\\_J-Ovic\\_uzUJ\\_iUQcqiKexF9jC4r2I](https://m.youtube.com/watch?v=msxnH-LeIM4&feature=share&fbclid=IwAR2B9Sf_kThKE8xlz1Ex8tRsufoiq_J-Ovic_uzUJ_iUQcqiKexF9jC4r2I)

**4. Adipose stem cell niche reprograms the colorectal cancer stem cell metastatic machinery.**

Di Franco S, Bianca P, Sardina DS, Turdo A, Gaggianesi M, **Veschi V**, Nicotra A, Mangiapane LR, Lo Iacono M, Pillitteri I, van Hooff S, Martorana F, Motta G, Gulotta E, Lentini VL, Martorana E, Fiori ME, Vieni S, Bongiorno MR, Giannone G, Giuffrida D, Memeo L, Colarossi L, Mare M, Vigneri P, Todaro M, De Maria R, Medema JP, Stassi G.

*Nat Commun*. 2021 Aug 18;12(1):5006. doi: 10.1038/s41467-021-25333-9. PMID: 34408135.

**IF: 17.694 Citations: 28**

PRESS/MEDIA RELEASE:

<https://www.unipa.it/Tumore-del-colon-lobesit-induce-la-formazione-delle-metastasi-00001/?fbclid=IwAR1qvbvdw3nGnl0YHvJyBepdfvZ7ZvzDSUG6C5mjQDpD3ZHpnZhf7LMG2DRk>

**5. Nobiletin and Xanthohumol Sensitize Colorectal Cancer Stem Cells to Standard Chemotherapy.**

Turdo A, Glaviano A, Pepe G, Calapà F, Raimondo S, Fiori ME, Carbone D, Basilicata MG, Di Sarno V, Ostacolo C, Parrino B, Cascioferro S, Pecoraro C, Di Franco S, Bellavia D, Gaggianesi M, **Veschi V**, Lo Iacono M, Ganduscio G, Pantina VD, Mangiapane LR, Bongiorno MR, Alessandro R, Todaro M, De Maria R, Diana P, Campiglia P, Stassi G.

*Cancers (Basel)*. 2021 Aug 4;13(16):3927. doi: 10.3390/cancers13163927. PMID: 34439086.

**IF: 6.575 Citations: 16**

**6. CHK1 inhibitor sensitizes resistant colorectal cancer stem cells to nortopsentin.**

Di Franco S, Parrino B, Gaggianesi M, Pantina VD, Bianca P, Nicotra A, Mangiapane LR, Lo Iacono M, Ganduscio G, **Veschi V**, Brancato OR, Glaviano A, Turdo A, Pillitteri I, Colarossi L, Cascioferro S, Carbone D, Pecoraro C, Fiori ME, De Maria R, Todaro M, Screpanti I, Cirrincione G, Diana P, Stassi G. *iScience*. 2021 May 29;24(6):102664. doi: 10.1016/j.isci.2021.102664. eCollection 2021 Jun 25. PMID: 34169240.

**IF: 6.107 Citations: 26**

**7. The Hippo Show Must Go On: Yap Activation as a Therapeutic Strategy in Colorectal Cancer.**

**Veschi V**, Stassi G.

*Cell Stem Cell*. 2020 Oct 1;27(4):501-502. doi: 10.1016/j.stem.2020.09.007. Preview. PMID: 33007230.

**IF: 24.633 Citations: 3**

**8. Cancer stem cells in Thyroid tumors: from the origin to metastasis.**

**Veschi V**, Verona F, Lo Iacono M, D'Accardo C, Porcelli G, Turdo A, Gaggianesi M, Forte S, Giuffrida D, Memeo L, Todaro M.

*Front Endocrinol (Lausanne)*. 2020 Aug 25;11:566. doi: 10.3389/fendo.2020.00566. eCollection 2020. Review. PMID: 32982967.

**IF: 5.555 Citations: 17**

**9. Targeting chemoresistant colorectal cancer via systemic administration of a BMP7 variant.**

**Veschi V**, Mangiapane LR, Nicotra A, Di Franco S, Scavo E, Apuzzo T, Sardina DS, Fiori M, Benfante A, Colorito ML, Cocorullo G, Giuliani F, Cipolla C, Pistone G, Bongiorno MR, Rizzo A, Tate CM, Wu X, Rowlinson S, Stancato LF, Todaro M, De Maria R, Stassi G.

*Oncogene*. 2020 Jan;39(5):987-1003. doi: 10.1038/s41388-019-1047-4. Epub 2019 Oct 7. PMID:31591478.

**IF: 9.867 Citations: 24**

PRESS/MEDIA RELEASE:

<https://www.google.com/amp/s/www.panorama.it/amp/la-proteina-che-rende-vulnerabili-le-cellule-tumoriali-2645951381?fbclid=IwAR2X6tW2Us9f-VeSwQvv1ptEDh0mvhCCEse3zZcctf8XtkjA0FrnVyvVUFQ>

**10. Targeting the Chromosomal Passenger Complex Subunit INCENP induces Polyploidization, Apoptosis, and Senescence in Neuroblastoma.**

Sun M, **Veschi V**, Bagchi S, Xu M, Mendoza A, Liu Z, Thiele CJ.

*Cancer Res*. 2019 Oct 1;79(19):4937-4950. doi: 10.1158/0008-5472.CAN-19-0695. Epub 2019 Aug 15. PMID: 31416840.

**IF: 9.727 Citations: 8**

**11. Microenvironment in neuroblastoma: isolation and characterization of tumor-derived mesenchymal stromal cells.**

Pelizzo G, **Veschi V\*** (co-first author), Mantelli M, Croce S, Di Benedetto V, D'Angelo P, Maltese A, Catenacci L, Apuzzo T, Scavo E, Moretta A, Todaro M, Stassi G, Avanzini MA, Calcaterra V.

*BMC Cancer*. 2018 Nov 27;18(1):1176. doi: 10.1186/s12885-018-5082-2. PMID:30482160

**\*Co-first author**

**IF: 2.933 Citations: 45**

**12. CRISPR-Cas9 screen reveals a MYCN-amplified neuroblastoma dependency on EZH2.**

Chen L, Alexe G, Dharia NV, Ross L, Iniguez AB, Conway AS, Wang EJ, **Veschi V**, Lam N, Qi J, Gustafson WC, Nasholm N, Vazquez F, Weir BA, Cowley GS, Ali LD, Pantel S, Jiang G, Harrington WF, Lee Y, Goodale A, Lubonja R, Krill-Burger JM, Meyers RM, Tsherniak A, Root DE, Bradner JE, Golub TR, Roberts CW, Hahn WC, Weiss WA, Thiele CJ, Stegmaier K.

*J Clin Invest*. 2018 Jan 2;128(1):446-462. doi: 10.1172/JCI90793. Epub 2017 Dec 4. PMID:29202477.

**IF: 12.282 Citations: 87**

## Part XII- Total Publications

### 1. Novel insights into cancer stem cells targeting: CAR-T therapy and epigenetic drugs as new pillars in cancer treatment.

**Veschi V.**, Turdo A. and Stassi G.

*Front. Mol. Med.* 18 May 2023. doi.org/10.3389/fmmed.2023.1120090

### 2. Recapitulating thyroid cancer histotypes through engineering embryonic stem cells.

**Veschi V.**, Turdo A., Modica C., Verona F., Di Franco S., Gaggianesi M., Tirro' E., Di Bella S., Lo Iacono M., Pantina V.D., Porcelli G., Mangiapane L. R., Bianca P., Rizzo A., Sciacca E., Pillitteri I., Vella V., Belfiore A., Bongiorno M.R., Pistone G., Memeo L., Colarossi L., Giuffrida D., Colarossi C., Vigneri P., Todaro M., and Stassi G.

*Nat Commun.* 2023 Mar 11;14(1):1351. doi: 10.1038/s41467-023-36922-1. PMID: 36906579.

**IF: 17.694 Citations: 1**

PRESS/MEDIA RELEASE:

<https://siciliamedica.com/articoli/tumore-avanzato-alla-tiroide-team-di-unipa-scopre-potenziabile-terapia/?fbclid=IwAR1oluiYuiT8oI1RCFa-xN95yL5gyb4-iTQFKnGHPMzqPH4wNyesVNYe7es>

<https://www.rainews.it/tgr/sicilia/notiziari/index.html?/tgr/video/2020/05/ContentItem-d2c4000a-f6e4-4317-8448-cf9cef0b8523.html> minutes 7:22-12:50

[https://www.unipa.it/Identificata-potenziabile-terapia-per-le-forme-avanzate-di-tumore-alla-tiroide--La-scoperta-del-team-UniPa-coordinato-dal-prof.-Giorgio-Stassi-pubblicata-su-Nature-Communications/?fbclid=IwAR1wTpl3Qy\\_Gf7bDr3zwt99o49HriYIUo58EfNwbq6gCYK7SHX\\_TW8FBYXY](https://www.unipa.it/Identificata-potenziabile-terapia-per-le-forme-avanzate-di-tumore-alla-tiroide--La-scoperta-del-team-UniPa-coordinato-dal-prof.-Giorgio-Stassi-pubblicata-su-Nature-Communications/?fbclid=IwAR1wTpl3Qy_Gf7bDr3zwt99o49HriYIUo58EfNwbq6gCYK7SHX_TW8FBYXY)

### 3. Cancer cell targeting by CAR-T cells: a matter of stemness.

D'Accardo C., Porcelli G., Mangiapane L. R., Modica C., Pantina V.D., Roozafzay N., Di Franco S., Gaggianesi M., **Veschi V.**, Lo Iacono M., Todaro M., Turdo A. and Stassi G.

*Front. Mol. Med.* 13 December 2022. doi:10.3389/fmmed.2022.1055028

### 4. Destroying the Shield of Cancer Stem Cells: Natural Compounds as Promising Players in Cancer Therapy.

Lo Iacono M., Gaggianesi M., Bianca P., Brancato O.R., Muratore G., Modica C., Roozafzay N., Shams K., Colarossi L., Memeo L., Turdo A., **Veschi V.**, Di Franco S., Todaro M., and Stassi G.

*J Clin. Med.* Published 26 November 2022. doi: 10.3390/jcm11236996.

**IF: 4.964 Citations: 0**

### 5. Targeting epigenetic alterations in cancer stem cells.

Verona F., Pantina V.D., Modica C., Lo Iacono M., D'Accardo C., Porcelli G., Cricchio D., Turdo A., Gaggianesi M., Di Franco S., Todaro M., **Veschi V.\***(co-corresponding author) and Stassi G\*.

*Front. Mol. Med.* 2:1011882. Published 20 September 2022. doi: 10.3389/fmmed.2022.1011882.

**\* Co-corresponding author**

### 6. Targeting of the Peritumoral Adipose Tissue Microenvironment as an Innovative Antitumor Therapeutic Strategy.

Lo Iacono M., Modica C., Porcelli G., Brancato OR, Muratore G, Bianca P, Gaggianesi M, Turdo A, **Veschi V.**, Todaro M, Di Franco S, Stassi G.

*Biomolecules.* 2022 May 14;12(5):702. doi:10.3390/biom12050702. PMID: 35625629.

**IF: 6.064 Citations: 1**

**7. Effective targeting of breast cancer stem cells by combined inhibition of Sam68 and Rad51.**

Turdo A, Gaggianesi M, Di Franco S, **Veschi V**, D'Accardo C, Porcelli G, Lo Iacono M, Pillitteri I, Verona F, Militello G, Zippo A, Poli V, Fagnocchi L, Beyes S, Stella S, Lattanzio R, Faldetta N, Lentini VL, Porcasi R, Pistone G, Bongiorno MR, Stassi G, De Maria R, Todaro M.

*Oncogene*. 2022 Apr;41(15):2196-2209. doi: 10.1038/s41388-022-02239-4. Epub 2022 Feb 25. PMID: 35217791.

**IF: 8.756 Citations: 4**

PRESS/MEDIA RELEASE:

[https://www.unipa.it/Cancro-al-seno--Studio-sostenuto-da-AIRC-e-coordinato-da-UniPa-identifica-un-mecanismo-che-determina-la-resistenza-alle-terapie-/?fbclid=IwAR3Wmytm3\\_lId9MHUZa0hFYz5bNaWM5wNKueQcGthJ6pR3ysRsJ\\_iKPF\\_-0](https://www.unipa.it/Cancro-al-seno--Studio-sostenuto-da-AIRC-e-coordinato-da-UniPa-identifica-un-mecanismo-che-determina-la-resistenza-alle-terapie-/?fbclid=IwAR3Wmytm3_lId9MHUZa0hFYz5bNaWM5wNKueQcGthJ6pR3ysRsJ_iKPF_-0)

[https://www.linkedin.com/posts/unipa-dichirons\\_effective-targeting-of-breast-cancer-stem-activity-6904443849490731009-mCIF?fbclid=IwAR1eV4LTftpYSbt-bnhxnQJ9LRvkXCeanNttUrWoSz63Wdxhyb50OoSf0Y](https://www.linkedin.com/posts/unipa-dichirons_effective-targeting-of-breast-cancer-stem-activity-6904443849490731009-mCIF?fbclid=IwAR1eV4LTftpYSbt-bnhxnQJ9LRvkXCeanNttUrWoSz63Wdxhyb50OoSf0Y)

<https://lnkd.in/dkc86SfP>

**8. Dual inhibition of Myc transcription and PI3K activity effectively targets colorectal cancer stem cells.**

Gaggianesi M, Mangiapane LR, Modica C, Pantina VD, Porcelli G, Di Franco S, Lo Iacono M, D'Accardo C, Verona F, Pillitteri I, Turdo A, **Veschi V**, Brancato OR, Muratore G, Pistone G, Bongiorno MR, Todaro M, De Maria R, Stassi G.

*Cancers (Basel)*. 2022 Jan 28;14(3):673. doi: 10.3390/cancers14030673. PMID: 35158939.

**IF: 6.575 Citations: 2**

**9. PI3K-driven HER2 expression is a potential therapeutic target in colorectal cancer stem cells.**

Mangiapane LR, Nicotra A, Turdo A, Gaggianesi M, Bianca P, Di Franco S, Sardina DS, **Veschi V**, Signore M, Beyes S, Fagnocchi L, Fiori ME, Bongiorno MR, Lo Iacono M, Pillitteri I, Ganduscio G, Gulotta G, Medema JP, Zippo A, Todaro M, De Maria R, Stassi G.

*Gut*. 2022 Jan;71(1):119-128. doi: 10.1136/gutjnl-2020-323553. Epub 2021 Jan 12. PMID: 33436496.

**IF: 31.795 Citations: 35**

PRESS/MEDIA RELEASE:

[https://www.fattieavvenimenti.it/palermo-il-tumore-al-colon-si-puo-sconfiggere-scoperto-punto-debole-al-policlinico-giacone/?fbclid=IwAR1hGrhAjmzR3fthJD-ykLeQAVo-No2E9s6vXtnX\\_veKp4o1piNPRXbsgkc](https://www.fattieavvenimenti.it/palermo-il-tumore-al-colon-si-puo-sconfiggere-scoperto-punto-debole-al-policlinico-giacone/?fbclid=IwAR1hGrhAjmzR3fthJD-ykLeQAVo-No2E9s6vXtnX_veKp4o1piNPRXbsgkc)

[https://m.youtube.com/watch?v=msxnH-LeIM4&feature=share&fbclid=IwAR2B9Sf\\_kThKE8xlz1Ex8tRsufoiq\\_J-Ovic\\_uzUJ\\_iUQcqiKexF9jC4r2I](https://m.youtube.com/watch?v=msxnH-LeIM4&feature=share&fbclid=IwAR2B9Sf_kThKE8xlz1Ex8tRsufoiq_J-Ovic_uzUJ_iUQcqiKexF9jC4r2I)

**10. Cancer Stem Cell Biomarkers Predictive of Radiotherapy Response in Rectal Cancer: A Systematic Review.**

Mare M, Colarossi L, **Veschi V**, Turdo A, Giuffrida D, Memeo L, Stassi G, Colarossi C.

*Genes (Basel)*. 2021 Sep 25;12(10):1502. doi: 10.3390/genes12101502. PMID: 34680897.

**IF: 4.141 Citations: 5**



- 11. Adipose stem cell niche reprograms the colorectal cancer stem cell metastatic machinery.**  
Di Franco S, Bianca P, Sardina DS, Turdo A, Gaggianesi M, **Veschi V**, Nicotra A, Mangiapane LR, Lo Iacono M, Pillitteri I, van Hooff S, Martorana F, Motta G, Gulotta E, Lentini VL, Martorana E, Fiori ME, Vieni S, Bongiorno MR, Giannone G, Giuffrida D, Memeo L, Colarossi L, Mare M, Vigneri P, Todaro M, De Maria R, Medema JP, Stassi G.  
*Nat Commun.* 2021 Aug 18;12(1):5006. doi: 10.1038/s41467-021-25333-9. PMID: 34408135.  
**IF: 17.694 Citations: 28**  
PRESS/MEDIA RELEASE:  
<https://www.unipa.it/Tumore-del-colon-lobesit-induce-la-formazione-delle-metastasi-00001/?fbclid=IwAR1qvbdw3nGnl0YHvJyBepdfvZ7ZvzDSUG6C5mjQDpD3ZHpnZhf7LMG2DRk>
- 12. Nobiletin and Xanthohumol Sensitize Colorectal Cancer Stem Cells to Standard Chemotherapy.**  
Turdo A, Glaviano A, Pepe G, Calapà F, Raimondo S, Fiori ME, Carbone D, Basilicata MG, Di Sarno V, Ostacolo C, Parrino B, Cascioferro S, Pecoraro C, Di Franco S, Bellavia D, Gaggianesi M, **Veschi V**, Lo Iacono M, Ganduscio G, Pantina VD, Mangiapane LR, Bongiorno MR, Alessandro R, Todaro M, De Maria R, Diana P, Campiglia P, Stassi G.  
*Cancers (Basel).* 2021 Aug 4;13(16):3927. doi: 10.3390/cancers13163927. PMID: 34439086.  
**IF: 6.575 Citations: 16**
- 13. Messing Up the Cancer Stem Cell Chemoresistance Mechanisms Supported by Tumor Microenvironment.**  
Gaggianesi M, Di Franco S, Pantina VD, Porcelli G, D'Accardo C, Verona F, **Veschi V**, Colarossi L, Faldetta N, Pistone G, Bongiorno MR, Todaro M, Stassi G.  
*Front Oncol.* 2021 Jul 20;11:702642. doi: 10.3389/fonc.2021.702642. eCollection 2021. PMID: 34354950.  
**IF: 5.738 Citations: 12**
- 14. CHK1 inhibitor sensitizes resistant colorectal cancer stem cells to nortopsentin.**  
Di Franco S, Parrino B, Gaggianesi M, Pantina VD, Bianca P, Nicotra A, Mangiapane LR, Lo Iacono M, Ganduscio G, **Veschi V**, Brancato OR, Glaviano A, Turdo A, Pillitteri I, Colarossi L, Cascioferro S, Carbone D, Pecoraro C, Fiori ME, De Maria R, Todaro M, Screpanti I, Cirrincione G, Diana P, Stassi G.  
*iScience.* 2021 May 29;24(6):102664. doi: 10.1016/j.isci.2021.102664. eCollection 2021 Jun 25. PMID: 34169240.  
**IF: 6.107 Citations: 26**
- 15. Targeting MYCN in Pediatric and Adult Cancers.**  
Liu Z, Chen SS, Clarke S, **Veschi V**, Thiele CJ.  
*Front Oncol.* 2021 Feb 8;10:623679. doi: 10.3389/fonc.2020.623679. eCollection 2020. PMID: 33628735.  
**IF: 5.738 Citations: 33**
- 16. The Hippo Show Must Go On: Yap Activation as a Therapeutic Strategy in Colorectal Cancer.**  
**Veschi V**, Stassi G.  
*Cell Stem Cell.* 2020 Oct 1;27(4):501-502. doi: 10.1016/j.stem.2020.09.007. Preview. PMID: 33007230.  
**IF: 24.633 Citations: 3**
- 17. Cancer stem cells in Thyroid tumors: from the origin to metastasis.**  
**Veschi V**, Verona F, Lo Iacono M, D'Accardo C, Porcelli G, Turdo A, Gaggianesi M, Forte S, Giuffrida D, Memeo L, Todaro M.  
*Front Endocrinol (Lausanne).* 2020 Aug 25;11:566. doi: 10.3389/fendo.2020.00566. eCollection 2020. Review. PMID: 32982967.  
**IF: 5.555 Citations: 17**



- 18. Targeting chemoresistant colorectal cancer via systemic administration of a BMP7 variant.**  
**Veschi V**, Mangiapane LR, Nicotra A, Di Franco S, Scavo E, Apuzzo T, Sardina DS, Fiori M, Benfante A, Colorito ML, Cocorullo G, Giuliani F, Cipolla C, Pistone G, Bongiorno MR, Rizzo A, Tate CM, Wu X, Rowlinson S, Stancato LF, Todaro M, De Maria R, Stassi G.  
*Oncogene*. 2020 Jan;39(5):987-1003. doi: 10.1038/s41388-019-1047-4. Epub 2019 Oct 7. PMID:31591478.  
**IF: 9.867 Citations: 24**  
PRESS/MEDIA RELEASE:  
<https://www.google.com/amp/s/www.panorama.it/amp/la-proteina-che-rende-vulnerabili-le-cellule-tumoriali-2645951381?fbclid=IwAR2X6tW2Us9f-VeSwQvv1ptEDh0mvhCCEse3zZcctf8XtkjA0FrnVyvVUFQ>
- 19. Cancer Stem Cells and Neuroblastoma: Characteristics and Therapeutic Targeting Options.**  
**Veschi V**, Verona F, Thiele CJ.  
*Front Endocrinol (Lausanne)*. 2019 Nov 19;10:782. doi:10.3389/fendo.2019.00782. eCollection 2019. Review. PMID: 31803140.  
**IF: 3.644 Citations: 19**
- 20. Targeting the Chromosomal Passenger Complex Subunit INCENP induces Polyploidization, Apoptosis, and Senescence in Neuroblastoma.**  
Sun M, **Veschi V**, Bagchi S, Xu M, Mendoza A, Liu Z, Thiele CJ.  
*Cancer Res*. 2019 Oct 1;79(19):4937-4950. doi: 10.1158/0008-5472.CAN-19-0695. Epub 2019 Aug 15. PMID: 31416840.  
**IF: 9.727 Citations: 8**
- 21. Meeting the challenge of targeting Cancer Stem Cells.**  
Turdo A, **Veschi V**, Gaggianesi M, Chinnici A, Bianca P, Todaro M, Stassi G.  
*Front Cell Dev Biol*. 2019 Feb 18;7:16. doi: 10.3389/fcell.2019.00016. eCollection 2019. Review. PMID:30834247.  
**IF: 5.186 Citations: 90**
- 22. Microenvironment in neuroblastoma: isolation and characterization of tumor-derived mesenchymal stromal cells.**  
Pelizzo G, **Veschi V\*** (co-first author), Mantelli M, Croce S, Di Benedetto V, D'Angelo P, Maltese A, Catenacci L, Apuzzo T, Scavo E, Moretta A, Todaro M, Stassi G, Avanzini MA, Calcaterra V.  
*BMC Cancer*. 2018 Nov 27;18(1):1176. doi: 10.1186/s12885-018-5082-2. PMID:30482160.  
**\*Co-first author**  
**IF: 2.933 Citations: 45**
- 23. CRISPR-Cas9 screen reveals a MYCN-amplified neuroblastoma dependency on EZH2.**  
Chen L, Alexe G, Dharia NV, Ross L, Iniguez AB, Conway AS, Wang EJ, **Veschi V**, Lam N, Qi J, Gustafson WC, Nasholm N, Vazquez F, Weir BA, Cowley GS, Ali LD, Pantel S, Jiang G, Harrington WF, Lee Y, Goodale A, Lubonja R, Krill-Burger JM, Meyers RM, Tsherniak A, Root DE, Bradner JE, Golub TR, Roberts CW, Hahn WC, Weiss WA, Thiele CJ, Stegmaier K.  
*J Clin Invest*. 2018 Jan 2;128(1):446-462. doi: 10.1172/JCI90793. Epub 2017 Dec 4. PMID:29202477.  
**IF: 12.282 Citations: 87**

**24. High-SETD8 inactivates p53 in neuroblastoma.**

**Veschi V**, Thiele CJ.

*Oncoscience*. 2017 Apr 14;4(3-4):21-22. doi: 10.18632/oncoscience.344. eCollection 2017 Mar. No abstract available. PMID:28540329

**Citations: 9**

**25. Epigenetic siRNA and Chemical Screens Identify SETD8 Inhibition as a Therapeutic Strategy for p53 Activation in High-Risk Neuroblastoma.**

**Veschi V**, Liu Z, Voss TC, Ozbun L, Gryder B, Yan C, Hu Y, Ma A, Jin J, Mazur SJ, Lam N, Souza BK, Giannini G, Hager GL, Arrowsmith CH, Khan J, Appella E, Thiele CJ.

*Cancer Cell*. 2017 Jan 9;31(1):50-63. doi: 10.1016/j.ccell.2016.12.002. PMID:28073004.

**IF: 22.844 Citations: 62**

PRESS/MEDIA RELEASE:

<https://ccr.cancer.gov/news/milestones-2018/article/new-player-on-the-scene>

<https://aacrjournals.org/cancerdiscovery/article/7/3/OF8/5805/SETD8-Inhibition-Activates-p53-in-High-Risk>

**26. Inhibition of STAT3 with the Generation 2.5 Antisense Oligonucleotide, AZD9150, Decreases Neuroblastoma Tumorigenicity and Increases Chemosensitivity.**

Odate S, **Veschi V**, Yan S, Lam N, Woessner R, Thiele CJ.

*Clin Cancer Res*. 2017 Apr 1;23(7):1771-1784. doi: 10.1158/1078-0432.CCR-16-1317. Epub 2016 Oct 19. PMID:27797972.

**IF: 10.199 Citations: 44**

**27. The MRN complex is transcriptionally regulated by MYCN during neural cell proliferation to control replication stress.**

Petroni M, Sardina F, Heil C, Sahún-Roncero M, Colicchia V, **Veschi V**, Albini S, Fruci D, Ricci B, Soriani A, Di Marcotullio L, Screpanti I, Gulino A, Giannini G.

*Cell Death Differ*. 2016 Feb;23(2):197-206. doi: 10.1038/cdd.2015.81. Epub 2015 Jun 12. PMID:26068589.

**IF: 8.339 Citations: 26**

**28. Galectin-3 is a marker of favorable prognosis and a biologically relevant molecule in neuroblastic tumors.**

**Veschi V**, Petroni M, Bartolazzi A, Altavista P, Dominici C, Capalbo C, Boldrini R, Castellano A, McDowell HP, Pizer B, Frati L, Screpanti I, Gulino A, Giannini G.

*Cell Death Dis*. 2014 Mar 6;5:e1100. doi: 10.1038/cddis.2014.68. PMID:24603328.

**IF: 5.014 Citations: 18**

**29. The HMGA1 protooncogene frequently deregulated in cancer is a transcriptional target of E2F1.**

Massimi I, Guerrieri F, Petroni M, **Veschi V**, Truffa S, Screpanti I, Frati L, Levrero M, Gulino A, Giannini G.

*Mol Carcinog*. 2013 Jul;52(7):526-34. doi: 10.1002/mc.21887. Epub 2012 Mar 2. PMID:22389255.

**IF: 4.770 Citations: 22**

**30. Galectin-3 impairment of MYCN-dependent apoptosis-sensitive phenotype is antagonized by nutlin-3 in neuroblastoma cells.**

**Veschi V**, Petroni M, Cardinali B, Dominici C, Screpanti I, Frati L, Bartolazzi A, Gulino A, Giannini G. *PLoS One*. 2012;7(11):e49139. doi: 10.1371/journal.pone.0049139. Epub 2012 Nov 9. PMID:23152863.

**IF: 3.730 Citations: 22**

**31. Molecular mechanisms of MYCN-dependent apoptosis and the MDM2-p53 pathway: an Achilles's heel to be exploited for the therapy of MYCN-amplified neuroblastoma.**

Petroni M, **Veschi V**, Gulino A, Giannini G.

*Front Oncol*. 2012 Oct 12;2:141. doi: 10.3389/fonc.2012.00141. eCollection 2012. PMID:23091802.

**IF: 4.416 Citations: 21**

**32. MYCN sensitizes human neuroblastoma to apoptosis by HIPK2 activation through a DNA damage response.**

Petroni M, **Veschi V\*(co-first author)**, Prodosmo A, Rinaldo C, Massimi I, Carbonari M, Dominici C, McDowell HP, Rinaldi C, Screpanti I, Frati L, Bartolazzi A, Gulino A, Soddu S, Giannini G.

*Mol Cancer Res*. 2011 Jan;9(1):67-77. doi: 10.1158/1541-7786.MCR-10-0227. Epub 2010 Dec 20. PMID:21173028.

**\*Co-first author**

**IF: 4.288 Citations: 31**

**33. Human papilloma virus-dependent HMGA1 expression is a relevant step in cervical carcinogenesis.**

Mellone M, Rinaldi C, Massimi I, Petroni M, **Veschi V**, Talora C, Truffa S, Stabile H, Frati L, Screpanti I, Gulino A, Giannini G.

*Neoplasia*. 2008 Aug;10(8):773-81. PMID:18670638.

**IF: 5.191 Citations: 17**

### **Part XIII- Publications indexed on Crossref (soon to be indexed on Pubmed and Scopus)**

**1. Novel insights into cancer stem cells targeting: CAR-T therapy and epigenetic drugs as new pillars in cancer treatment.**

**Veschi V**, Turdo A. and Stassi G.

*Front. Mol. Med*. 18 May 2023. doi.org/10.3389/fmmed.2023.1120090

**2. Cancer cell targeting by CAR-T cells: a matter of stemness.**

D'Accardo C., Porcelli G., Mangiapane L. R., Modica C., Pantina V.D., Roozafzay N., Di Franco S., Gaggianesi M., **Veschi V**, Lo Iacono M., Todaro M., Turdo A. and Stassi G.

*Front. Mol. Med*. 13 December 2022. doi:10.3389/fmmed.2022.1055028

**3. Targeting epigenetic alterations in cancer stem cells.**

Verona F., Pantina V.D., Modica C., Lo Iacono M., D'Accardo C., Porcelli G., Cricchio D., Turdo A., Gaggianesi M., Di Franco S., Todaro M., **Veschi V\*(co-corresponding author)** and Stassi G\*.

*Front. Mol. Med*. 2:1011882. Published 20 September 2022. doi: 10.3389/fmmed.2022.1011882.

**\* Co-corresponding author**

## **Part XIV- Meeting Acta published on International Journals indexed on ISI Web of Science**

**1.** Targeting chromosomal passenger complex by disruption of INCENP function inhibits tumor progression in neuroblastoma.

Sun M, **Veschi V**, Lam N, Bagchi S, Xu M, Mendoza A, Liu Z, Thiele CJ.

*Cancer Research* 2019 July 1; 79 (13 Supplement), 2537-2537.

**IF: 9.727**

**2.** Developing selective SETD8 inhibitors for treating high-risk neuroblastoma.

Ma A, **Veschi V**, Yu W, Babault N, Li F, Butler K, Wang J, Luo M, Vedadi M, Brown P, Arrowsmith C, Thiele CJ, Jin J.

*ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY*. 2018 August 19. Volume 256

**3.** Epigenetic siRNA and chemical screens identify SETD8 inhibition as a therapeutic strategy to reactivate p53 in high-risk Neuroblastoma.

**Veschi V**, Liu Z, Voss T C., Ozbun L, Gryder B, Yan C, Hu Y, Ma A, Jin J, Mazur SJ, Lam N, Souza BK, Giannini G, Hager GL, Arrowsmith C, Khan J, Appella E and Thiele CJ.

*Cancer Research*. 2017 July; 77 (13 Supplement), 3867-3867.

**IF: 9.170**

**4.** Inhibition of STAT3 with the generation 2.5 antisense oligonucleotide, AZD9150 increases the chemosensitivity and decreases tumor-initiating potential of neuroblastoma cells.

Odate S, Yan S, **Veschi V**, Lam N, Liu Z, Thiele CJ.

*Cancer Research*. 2016 July; 76 (14 Supplement), 2439-2439

**IF: 9.122**

**5.** Whole genome screen to identify genes targeting MYCN-driven embryonal tumors.

Thiele CJ, Liu Z, **Veschi V**, Buehler E, Martin S.

*Cancer Research*. 2015 August 1; 75 (15 Supplement), 487-487

**IF: 8.556**

Rome, 19<sup>th</sup> June 2023